Consumption of fructose- but not glucose-sweetened beverages for 10 weeks increases circulating concentrations of uric acid, retinol binding protein-4, and gamma-glutamyl transferase activity in overweight/obese humans by Chad L Cox et al.
Cox et al. Nutrition & Metabolism 2012, 9:68
http://www.nutritionandmetabolism.com/content/9/1/68RESEARCH Open AccessConsumption of fructose- but not glucose-
sweetened beverages for 10 weeks increases
circulating concentrations of uric acid, retinol
binding protein-4, and gamma-glutamyl
transferase activity in overweight/obese humans
Chad L Cox2, Kimber L Stanhope1,2, Jean Marc Schwarz3, James L Graham1,2, Bonnie Hatcher2, Steven C Griffen4,
Andrew A Bremer5, Lars Berglund4, John P McGahan7, Nancy L Keim2,6 and Peter J Havel1,2*Abstract
Background: Prospective studies in humans examining the effects of fructose consumption on biological markers
associated with the development of metabolic syndrome are lacking. Therefore we investigated the relative effects
of 10 wks of fructose or glucose consumption on plasma uric acid and RBP-4 concentrations, as well as liver
enzyme (AST, ALT, and GGT) activities in men and women.
Methods: As part of a parallel arm study, older (age 40–72), overweight and obese male and female subjects (BMI
25–35 kg/m2) consumed glucose- or fructose-sweetened beverages providing 25% of energy requirements for 10
wks. Fasting and 24-h blood collections were performed at baseline and following 10 wks of intervention and
plasma concentrations of uric acid, RBP-4 and liver enzyme activities were measured.
Results: Consumption of fructose, but not glucose, led to significant increases of 24-h uric acid profiles (P< 0.0001)
and RBP-4 concentrations (P= 0.012), as well as plasma GGT activity (P= 0.04). Fasting plasma uric acid
concentrations increased in both groups; however, the response was significantly greater in subjects consuming
fructose (P= 0.002 for effect of sugar). Within the fructose group male subjects exhibited larger increases of RBP-4
levels than women (P= 0.024).
Conclusions: These findings suggest that consumption of fructose at 25% of energy requirements for 10 wks,
compared with isocaloric consumption of glucose, may contribute to the development of components of the
metabolic syndrome by increasing circulating uric acid, GGT activity, suggesting alteration of hepatic function, and
the production of RBP-4.Background
Between 1970 and 2005 there has been a 19% increase
in the consumption of added sugars and sweeteners in
the U.S. [1]. Current estimations suggest that sweetener
consumption in the U.S. has increased to an average of
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reproduction in any medium, provided the or2000 kcal/day diet [1]. The monosaccharide fructose is
a primary component of both of the two most com-
mon sweeteners in the U.S., sucrose and high fructose
corn syrup. An increase in the consumption of sweet-
eners containing fructose has occurred in parallel with
the increasing prevalence of overweight and obesity
over the past three decades [2], suggesting that
increased consumption of fructose may contribute to
the current epidemic of obesity-related metabolic disor-
ders [2,3] including increased incidence of the meta-
bolic syndrome [4,5].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sweetened beverages for 10 wks, at 25% of energy
requirements, increases several risk factors for the meta-
bolic syndrome in older (age 40–72), overweight/obese
humans (BMI 25–35 kg/m2) as compared to isocaloric
glucose consumption [6]. Consumption of fructose, but
not glucose led to increased hepatic de novo lipogenesis
(DNL), and promoted accumulation of intra-abdominal
fat, the development of a more atherogenic lipid profile,
and reduced insulin sensitivity in overweight/obese
adults [6]. We have hypothesized that the increased rate
of DNL following consumption of fructose leads to an
accumulation of hepatic lipid, which promotes dyslipide-
mia and decreased insulin sensitivity [7].
Evidence suggests that elevated levels of uric acid and
increased activity of the liver enzymes gamma-glutamyl
transferase (GGT) and alanine aminotransferase (ALT)
are also associated with development of the metabolic
syndrome [8,9]. Fructose has been demonstrated to in-
crease circulating uric acid concentrations in both animals
and humans, and elevated concentrations of uric acid are
correlated with increased fructose intake [10,11]. It has
been suggested that fructose-induced hyperuricemia may
mediate some of the abnormalities associated with meta-
bolic syndrome including hypertriglyceridemia, insulin re-
sistance and hypertension [10]. Elevated serum uric acid
levels have also been found to be associated with the de-
velopment of cirrhosis and increased plasma activity of
GGT and ALT [12]. GGT and ALT activities (and to a
lesser extent aspartate aminotransferase (AST)) have been
shown to be strong predictors of metabolic syndrome and
are considered to be markers of non-alcoholic fatty liver
disease (NAFLD) [13,14]. Uric acid levels have also been
found to be strongly associated with concentrations of the
recently described adipokine retinol binding protein-4
(RBP-4) [15]. Increased circulating concentrations of RBP-
4 have been linked with increased visceral adiposity [16]
and have been shown to directly contribute to hepatic in-
sulin resistance via induction of hepatic glucose produc-
tion [17] and impairment of insulin signaling in muscle
[15,18]. To determine if fructose-induced changes of
DNL, intra-abdominal fat deposition, circulating lipids
and insulin sensitivity [6] were accompanied by increases
of these biological markers associated with the develop-
ment of metabolic syndrome, 24-h plasma uric acid levels
as well as fasting concentrations of RBP-4 and activities of
the liver enzymes GGT, AST and ALT were measured in
overweight/obese men and women consuming fructose-
or glucose-sweetened beverages for 10 wks.
Methods
Study design
This was a parallel arm study with 3 phases: 1) a 2-wk in-
patient baseline period; 2) an 8-wk outpatient interventionperiod; and 3) a 2-wk inpatient intervention period.
During baseline, subjects resided in the University of
California-Davis Clinical and Translational Science
Center’s Clinical Research Center (CCRC) for 2 wks.
Subjects then began the 8-wk outpatient intervention
and consumed either fructose- (n= 17) or glucose-
sweetened (n= 15) beverages at 25% of energy require-
ments with self-selected ad libitum diets. Subjects
returned to the CCRC for the final 2 wks of interven-
tion during which the glucose- or fructose-sweetened
beverages were consumed as part of an energy-
balanced diet.
Subjects
Participants were recruited through newspaper adver-
tisements and underwent a telephone and an in-person
interview with medical history, a complete blood
count, and a serum biochemistry panel to assess eligi-
bility. Inclusion criteria included age 40–72 years and
BMI 25–35 kg/m2 with a self-report of stable body
weight during the prior six months. Women were
post-menopausal based on a self-report of no menstru-
ation for at least one year. Exclusion criteria included:
evidence of diabetes, renal or hepatic disease, fasting
serum triglyceride (TG) concentrations >400 mg/dl,
hypertension (>140/90 mm Hg), and surgery for
weight loss. Individuals who smoked, reported exercise
of more than 3.5 hours/wk at a level more vigorous
than walking, or having used thyroid, lipid-lowering,
glucose-lowering, anti-hypertensive, anti-depressant, or
weight loss medications were also excluded. Diet-
related exclusion criteria included habitual ingestion of
more than one sugar-sweetened beverage/day (12 ounces
or ~350 mL) or more than two alcoholic beverages/day
(one alcoholic beverage is defined as 5 ounces of wine,
12 ounces of beer, 8 ounces of malt liquor, or 1.5 ounces
of spirits (80 proof) which is equivalent to 14 grams or
0.6 ounces of ethanol). The UCD Institutional Review
Board approved the experimental protocol, and subjects
provided informed consent to participate in the study.
Thirty-nine subjects enrolled in the study and experi-
mental groups were matched for gender, BMI, and fast-
ing TG and insulin concentrations. As reported by
Stanhope et al., baseline anthropometric and metabolic
characteristics did not differ between the two experi-
mental groups (Table 1) [6]. Seven subjects (3 in the glu-
cose group, 4 in the fructose group) did not complete
the study because of inability/unwillingness to comply
with the protocol or due to personal or work-related
conflicts. We were unable to measure uric acid, liver
enzymes or RBP-4 in one female subject in the fructose
group due to a lack of plasma samples. We were also
unable to collect a complete set of 24-h blood samples
from one subject in the glucose group. Therefore, 24-h
Table 1 Baseline anthropometric & metabolic parameters
Parameter Glucose Fructose
Male (n = 7) Female (n = 8) Male (n = 9) Female (n = 8)
Age (yr) 54 ± 3 56 ± 2 52± 4 53 ± 2
Weight (kg) 88.4 ± 2.9 84.0 ± 4.5 89.3 ± 2.9 81.9 ± 4.2
BMI (kg/m2) 29.3 ± 1.1 29.4 ± 1.3 28.4 ± 0.7 30.3 ± 1.0
Waist circumference (cm) 98.9 ± 2.6 91.0 ± 4.0 97.3 ± 3.3 91.8 ± 4.4
Body Fat (%) 29.4 ± 1.1 43.2 ± 1.5 28.5 ± 1.3 39.6 ± 2.2
TG (mg/dl) 148 ± 31 145± 23 131± 21 159 ± 30
Total Cholesterol (mg/dl) 179 ± 14 193± 10 176± 6 198 ± 15
HDL (mg/dl) 36 ± 3 41 ± 3 39± 4 41 ± 3
LDL (mg/dl) 124 ± 5 123± 11 107± 7 124 ± 15
Glucose (mg/dl) 89 ± 2 89 ± 3 88± 1 90 ± 1
Insulin (μU/ml) 14.3 ± 3.2 15.6 ± 2.9 12.0 ± 1.6 16.3 ± 2.5
GLM 2-factor ANOVA (type of sugar & gender). There were no significant differences among groups. Data represent mean± SEM.
Data previously published: Stanhope KL, et al. (2009). J Clin Invest 119: 1322–1334.
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n = 16, glucose: n = 14), while all other measurements
were calculated with n = 31 (fructose: n = 16, glucose:
n = 15).Diets
During the inpatient metabolic phases, subjects con-
sumed diets designed to maintain energy balance pro-
viding 15% of energy as protein, 30% as fat, and 55%
as carbohydrate. Subjects were required to consume all
of the food and were limited to only the food provided.
Daily energy intake was based on an estimate of energy
needed to maintain body weight, calculated at baseline
using the Mifflin equation to estimate resting energy
expenditure [19] and adjusted for activity using a
multiplication factor of 1.3 on the day of 26-h stable
isotope infusions and 24-h serial blood collections, and
a factor of 1.5 for other inpatient days. Energy intake
was distributed across the day: 25% at breakfast
(09:00 h), 35% at lunch (13:00 h), and 40% at dinner
(18:00 h). During baseline, the carbohydrate content
consisted primarily of complex carbohydrates. For the
final 2-wk inpatient intervention period, subjects con-
sumed diets at the baseline energy level and macronu-
trient composition except that 30% of energy was from
complex carbohydrates and 25% was provided by
fructose- or glucose-sweetened beverages. The macro-
nutrient and micronutrient content of the diets con-
sumed by the two experimental groups during the
inpatient baseline and inpatient intervention phases of
the study was identical, with the exception of the
sugars provided in the beverages. Additional details
about the dietary intake for inpatient and outpatient
phases have been described previously [6].Meals consumed during and prior to 24-h blood
collections
Intervention meals (10 wk) were matched as closely as
possible to the baseline meals (0 wk), except for the
substitution of 25% of energy from sugars for the com-
plex carbohydrate. The baseline (0 wk) and final (10
wk) intervention 24-h blood collections were performed
after subjects had consumed energy-balanced, weight-
maintaining diets in the CCRC for 10 days.
24-hour fasting and postprandial blood profiles
24-h blood collections were conducted during baseline
(0 wk) and after 10 wks of intervention (10 wk). At
07:30 h, an i.v. catheter was inserted into an arm vein by
a Registered Nurse and kept patent with slow saline in-
fusion. Three fasting blood samples were collected in
EDTA at 08:00, 08:30, and 09:00 h. Thirty-three post-
prandial blood samples were collected at 30–60 minute
intervals from 09:30 until 08:00 h the next morning
[20,21]. Meals were served at 09:00, 13:00 and 18:00 h.
An additional 3–6 ml of blood was collected at each of
the following time-points: 08:00, 08:30, 09:00 and 22:00,
23:00, 23:30 h. The plasma from the 3 fasting samples
(08:00, 08:30, 09:00 h) was pooled, as was the plasma
from the 3 postprandial blood samples (22:00, 23:00,
23:30 h); multiple aliquots of each pooled sample were
stored at −80 °C.
Uric Acid, RBP-4, GGT, AST and ALT
Uric Acid was measured using a colorimetric assay from
Wako (Richmond, VA). RBP-4 was quantified using an
ELISA from R&D Systems (Minneapolis, MN) and GGT,
AST and ALT activities were determined using a Poly-
chem Chemistry Analyzer (PolyMedCo, Inc., Cortlandt
Manor, NY).
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Average 24-h uric acid and TG exposure were deter-
mined by averaging values for the 33 postprandial time
periods. Peak TG exposure was defined as the highest
TG measurement over the 33 postprandial time periods,
and postprandial TG peak was calculated by averaging
TG measurements taken at 22:00, 23:00, and 23:30 h.
Statistical tests were performed with SAS 9.2. The per-
cent change for each outcome was calculated and ana-
lyzed in a 3-factor (type of sugar, gender, and presence
of metabolic syndrome) mixed procedures analysis using
PROC MIXED. Outcomes with least squares means (LS
means) of the change (10wk versus 0wk) significantly
different than zero were identified. Risk factors for meta-
bolic syndrome (MSRFs) were identified in all subjects
and the presence of metabolic syndrome was defined as
having at least 3 MSRFs (subjects with metabolic syn-
drome: Fructose n = 5, Glucose n = 4; subjects without
metabolic syndrome: Fructose n = 11, Glucose n = 11).
MSRFs were those defined by the American Heart Asso-
ciation/National Heart Lung and Blood Institute [22,23].
The percent change in response variables between 0 and
10 wks was determined, and Pearson’s correlation coeffi-
cients describing the relationship between response vari-
ables were calculated using PROC CORR. Statistical
tests with P values <0.05 were considered significant.
Data are presented as mean ± SEM.
Results
Fasting uric acid and 24-h circulating uric acid profiles
At 10 wks of intervention fasting plasma uric acid
concentrations were significantly increased from base-
line in subjects consuming both fructose- (absolute
Δ=+0.82 ± 0.08 mg/dL; P< 0.0001) and glucose-
sweetened (absolute Δ=+0.23 ± 0.09 mg/dL; P= 0.02)
beverages, but the effect was significantly greater in those
consuming fructose-sweetened beverages (P= 0.002 forTable 2 Baseline values and % change at 10 wks of intervent







24-h Uric Acid Exposure (mg/dL) 5.64 ± 0.14 6.05 ± 0.16 7.2
Fasting Uric Acid (mg/dL) 5.70 ± 0.11 6.40 ± 0.13 11.9
2RBP-4 (ug/mL) 23.0 ± 1.1 25.2 ± 1.5 9.9
3GGT (U/L) 23.0 ± 4.1 26.7 ± 4.4 17.7
AST (U/L) 17.3 ± 1.6 16.1 ± 1.2 −3.7
ALT (U/L) 14.5 ± 1.6 13.7 ± 1.8 −5.2
1Values are means ± SEM, n = 31 (fructose n = 16; glucose n = 15) for all measuremen
PROC MIXED 3-factor (sugar, gender, and presence of metabolic syndrome) ANOVA
sugar ×metabolic syndrome: P= 0.002.
*P< 0.05, **P< 0.01, ***P< 0.001 for changes significantly different from zero.effect of sugar) (Table 2). 24-h serum uric acid profiles
were increased significantly from baseline in subjects
consuming fructose (absolute Δ=+0.42 ± 0.05 mg/dL;
P< 0.0001) but not in those consuming glucose (absolute
Δ=+0.07 ± 0.03 mg/dL; P= 0.26) (P< 0.0001 for effect of
sugar) (Table 2) (Figure 1).
Fasting RBP-4
After 10 wks fasting plasma RBP-4 concentrations
increased significantly from baseline in subjects con-
suming fructose-sweetened beverages (absolute Δ=+2.2
± 1.0 ng/mL; P= 0.012) and decreased significantly
from baseline in those consuming glucose-sweetened
beverages (absolute Δ=−3.7 ± 0.9 ng/mL; P= 0.0005)
(P< 0.0001 for effect of sugar) (Table 2). Although
RBP-4 concentrations decreased comparably in both
men and women in the glucose group, the increase of
RBP-4 from baseline levels in subjects consuming fruc-
tose was significantly greater in men (P= 0.007) com-
pared to women (P= 0.908) (P= 0.024 for effect of
sugar × gender) (Figure 2).
Plasma GGT, AST, and ALT Activities
Plasma GGT activity was significantly elevated compared
with baseline values following 10 wks of fructose con-
sumption (absolute Δ=+3.7 ± 1.1 U/L; P= 0.04) but
decreased significantly in subjects consuming glucose
(absolute Δ = −6.4 ± 2.6 U/L; P< 0.0001)(P< 0.0001 for
effect of sugar) (Table 2). The increases of GGT at 10
wks in subjects consuming fructose were greater in
those with less than 3 MSRFs (Baseline: 23.0 ± 5.1 U/L,
absolute Δ=+4.1 ± 1.4 U/L) as compared to those with
metabolic syndrome (≥3 MSRFs) (Baseline: 23.1 ± 7.3
U/L, absolute Δ=+2.7 ± 1.9 U/L) (P= 0.002 for effect of
MSRF and P= 0.002 for effect of sugar ×MSRF). Fasting
activities of AST and ALT decreased slightly following
10 wks of fructose consumption; however, these changesion for fasting uric acid levels, mean 24-h uric acid












± 1.1*** 5.67 ± 0.18 5.74 ± 0.18 1.3 ± 1.1 < 0.0001
± 0.6*** 5.42 ± 0.16 5.65 ± 0.18 4.3 ± 1.5* 0.002
± 4.1* 28.2 ± 1.4 24.5 ± 1.3 −12.5 ± 3.0** < 0.0001
± 5.2* 40.2 ± 9.6 33.8 ± 7.6 −10.7 ± 4.0*** < 0.0001
± 4.9 22.3 ± 2.3 17.8 ± 1.0 −13.1 ± 6.2** 0.08
± 4.4 20.6 ± 3.2 13.7 ± 1.2 −22.3 ± 6.7 ** 0.04
ts except 24-h uric acid exposure (n = 30, fructose n = 16, glucose n= 14).
; 2sugar × gender: P =0.037; 3effect of metabolic syndrome: P= 0.002,













































Figure 1 Circulating uric acid concentrations over 24-h in subjects before and after 10 wks of consuming (A) fructose- or (B)
glucose- sweetened beverages. ***P< 0.0001 compared with baseline and P< 0.0001 for effect of sugar using PROC mixed 3-factor (sugar,
gender, and presence of metabolic syndrome) ANOVA; glucose, n = 14; fructose, n = 16. Data represent mean± SEM.
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consuming glucose both AST (absolute Δ=−4.5 ± 2.2
U/L, P= 0.002; effect of sugar: P= 0.08) and ALT (abso-
lute Δ=−6.9 ± 3.0 U/L, P= 0.002; effect of sugar:
P= 0.04) activities were decreased after 10 wks (Table 2).Table 3 Correlations between selected response variables
(% change)Relationships between response variables
In subjects consuming fructose the percent increases of
both fasting concentrations of RBP-4 and GGT activity,
but not uric acid concentrations, were positively asso-
ciated with previously reported increases of TG exposure,
peak TG exposure, and postprandial TG peak (Table 3)
(Figure 3) [6]. These relationships were not observed in
subjects consuming glucose (Table 3). There were no sig-
nificant relationships observed between elevations of uric
acid and RBP-4 levels or GGT activity, nor between eleva-






























Figure 2 Percent changes of fasting RBP-4 concentrations after
10 wks of consuming fructose- or glucose-sweetened
beverages in male and female subjects. Values are means ± SEM,
n = 31 (fructose group, n = 16; glucose group, n = 15) PROC MIXED
3-factor (sugar, gender, and presence of metabolic syndrome)
ANOVA; *P< 0.05 and **P< 0.01 for changes significantly different
from baseline.Discussion
To our knowledge, this is the first study to report that
prolonged fructose consumption increases 24-h circulat-
ing uric acid concentrations, GGT activity and RBP-4
levels in humans. Importantly, these findings also comple-
ment our previously reported results (in these same sub-
jects) which demonstrated that hepatic fractional de novo
lipogenesis (DNL) and plasma lipids and lipoprotein con-
centrations increased in subjects consuming fructose-
sweetened beverages, but remained unchanged in subjects
consuming glucose-sweetened beverages for 10 wks [6].
Despite comparable weight gain (~1-2% of initial body
weight), subjects consuming fructose primarily exhibited
increases of visceral adipose tissue (VAT), whereas onlyResponse variables;
percent change
Fructose (n = 16) Glucose (n = 15)
RBP-4 vs. peak TG exposure r=0.719 r=−0.011
P= 0.002** P= 0.969
GGT vs. peak TG exposure r=0.498 r= 0.152
P= 0.049* P= 0.603
RBP-4 vs. 24-h TG exposure r=0.653 r= 0.081
P= 0.006** P= 0.783
GGT vs. 24-h TG exposure r=0 .618 r= 0.072
P= 0.011* P= 0.806
RBP-4 vs. postprandial TG peak r=0.575 r=−0.055
P= 0.020* P= 0.851
GGT vs. postprandial TG peak r=0.601 r= 0.178
P= 0.014* P= 0.542
Pearson’s correlation coefficients (r) describing the relationship between
response variables (% change) were calculated using PROC CORR. Average 24-h
TG exposure was determined by averaging values for the 33 postprandial time
periods. Peak TG exposure was defined as the highest TG measurement over
the 33 postprandial time periods, and postprandial TG peak was calculated by
averaging TG measurements taken at 22:00, 23:00, and 23:30 h. *P< 0.05 **
P< 0.01.















































Figure 3 Correlations between the percent changes of 24-h TG exposure and percent changes of (A) RBP-4 levels and (B) GGT activity
in subjects consuming fructose. Pearson’s correlation coefficients (r) were calculated using PROC CORR. Average 24-h TG exposure was
determined as the mean of TG concentrations in the 33 postprandial samples. n = 31 (fructose group n= 16).
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jects consuming glucose [6]. In addition, indices of insulin
sensitivity and glucose tolerance were decreased during 10
wks of fructose consumption, but were unaffected by iso-
caloric consumption of glucose [6].
Uric acid
Prolonged fructose consumption significantly increased
both fasting uric acid concentrations and 24-h uric acid
exposure. The increase of fasting uric acid concentra-
tions exhibited after 10 wks of fructose consumption is
consistent with previous reports of the effects of up to 5
wks of fructose consumption at 20-30% of total calories
in humans [24-26]. Reiser et al. demonstrated that con-
sumption of 20% of energy from fructose for 5 wks as
part of a diet designed to maintain body weight
increased fasting uric acid levels in men [25] and our
results support these findings.
The mechanism by which fructose consumption
leads to increased uric acid concentrations is thought
to be initiated by the depletion of adenosine triphos-
phate (ATP) and inorganic phosphate (Pi) resulting
from unregulated production of fructose-1-phosphate
and glyceraldehyde-3-phosphate from fructose, which
bypasses the rate-limiting step of glycolysis, phospho-
fructokinase (PFK) [3,27]. Fructose-induced depletion
of ATP and Pi leads to a concomitant increase of pur-
ine nucleotide degradation and, subsequently, uric acid
production [27]. It has also been reported that, in
addition to increased nucleotide degradation, prolonged
fructose consumption promotes increases in the in-
corporation of glycine into urate suggesting that upre-
gulation of de novo purine nucleotide synthesis may
also contribute to fructose-induced increases of uric
acid [28]. While uric acid is a potent and physiologic-
ally relevant antioxidant, recent evidence suggests that
elevated levels may be associated with increased oxida-
tive stress, and there is still considerable debate as towhich of these roles is more important in the context
of metabolic disease [29].
Elevations of fasting uric acid levels have been shown to
be associated with hypertriglyceridemia and insulin resist-
ance [30,31]. Our results are not consistent with these
findings as we did not detect any relationships between
changes in fasting uric acid levels or 24-h uric acid expos-
ure and the previously reported marked increases of TG
exposure or reductions of insulin sensitivity in subjects
consuming fructose [6]. Also in contrast to the findings of
previous investigations [12,15], increases of fasting uric
acid concentrations and 24-h uric acid exposure were not
associated with elevations of RBP-4 levels or GGT activity.
Although we did not detect a correlation between eleva-
tions of uric acid and changes of TG exposure, insulin
sensitivity, RBP-4 levels or GGT activity, it is important to
point out that our sample size was fairly modest and thus
these findings do not rule a contribution of uric acid to
the reported changes in these metabolic parameters. Add-
itional intervention studies are needed to investigate the
possibility that these changes are related. It is interesting
that fasting uric acid concentrations (but not 24-h uric
acid exposure) also increased significantly in subjects con-
suming glucose-sweetened beverages for 10 wks despite
the fact that these subjects did not exhibit any of the ad-
verse changes measured in subjects consuming fructose
[6]. This finding suggests that changes of 24-h uric acid
exposure may be a more sensitive indicator of increased
metabolic dysfunction than changes of fasting levels.
RBP-4
No previous studies have investigated the effects of glu-
cose or fructose consumption on circulating levels of
RBP-4. There is increasing evidence suggesting that
RBP-4 may be an important link between increases of
visceral adiposity and insulin resistance [32]. In animal
studies RBP-4 has been clearly shown to reduce glucose
uptake and impair insulin signaling in muscle, as well as
Cox et al. Nutrition & Metabolism 2012, 9:68 Page 7 of 10
http://www.nutritionandmetabolism.com/content/9/1/68to increase hepatic glucose production via induction of
the gluconeogenic enzyme phosphoenolpyruvate carbox-
ykinase (PEPCK) [17]. In humans, increases of circulat-
ing RBP-4 are strongly associated with insulin resistance
in adipose tissue [33], and elevations of circulating RBP-
4 are predictive of a diagnosis of metabolic syndrome
[34]. While hepatocytes are the primary source of
RBP-4, it has been demonstrated that adipocytes can
also contribute significantly to circulating concentra-
tions of RBP-4 [35]. Reduced expression of the insulin-
stimulated glucose transporter, GLUT4, in adipocytes
has been shown to lead directly to increased adipocyte
secretion of RBP-4 [33]. Moreover, expression of RBP-
4 in humans is significantly greater in visceral adipose
tissues (VAT) compared with subcutaneous adipose tis-
sue (SAT) and is associated with an increase of adipo-
cyte size [16].
Circulating RBP-4 concentrations are significantly ele-
vated following 10 wks of fructose consumption (Table 2)
and these changes are correlated with increases of post-
prandial TG (Table 3, Figure 3). We have hypothesized
that fructose consumption can promote reductions in in-
sulin sensitivity by providing substrate for hepatic DNL
leading to hepatic triglyceride accumulation, PKC activa-
tion, and increased hepatic insulin resistance [7] and have
suggested that this mechanism is responsible for the
reductions in insulin sensitivity previously reported in
these same subjects [6]. Although the reported increases
of RBP-4 were relatively modest, our results suggest the
possibility that fructose-induced increases of RBP-4 levels
may also have contributed to the previously reported
reductions of insulin sensitivity in these subjects [6].
We have suggested that the differential effects of fruc-
tose and glucose on regional adipose deposition may be
explained in part by the increased sensitivity of SAT
relative to VAT to insulin-stimulated lipoprotein lipase
(LPL) activation [6], and by our reported observations
that insulin responses were decreased in subjects con-
suming fructose and increased in subjects consuming
glucose [36]. The differential changes in RBP-4 levels in
subjects consuming fructose or glucose are consistent
with this mechanism considering that reductions of
post-meal insulin exposure in subjects consuming fruc-
tose would lead to decreased expression of GLUT4 in
adipocytes, which would be expected to be associated
with an increase in the production and secretion of
RBP-4 from adipose tissue (VAT in particular). Thus, it
is possible that reduced insulin exposure in subjects con-
suming fructose led to increased plasma RBP-4 levels
directly by decreasing expression of GLUT4 in adipose
tissue, and indirectly by increasing deposition of TG into
VAT, leading to increased visceral adipocyte size, and
increased secretion of RBP-4. The significant reduction
of circulating RBP-4 concentrations observed in subjectsconsuming glucose-sweetened beverages is consistent
with the observations that glucose consumption did not
result in increased DNL, postprandial hypertriglyceride-
mia, accumulation of VAT or reduced postprandial insu-
lin exposure [6].
The finding that increases of RBP-4 during fructose
consumption were larger in men than in women was
not unexpected considering that TG responses and
increases of VAT deposition were also considerably
greater in men [6] (Figure 2). We have also reported that
women exhibited greater decreases in insulin sensitivity
than men in response to fructose consumption, and have
hypothesized that this may be due to decreased rates of
VLDL production and secretion, leading to larger
increases of hepatic lipid [6]. Our findings suggest that
the increased rate of VLDL production/secretion follow-
ing fructose consumption in men is accompanied by an
increase of RBP-4 levels. These elevations of RBP-4
levels are likely the result of increased accumulation of
VAT and decreased insulin-stimulated GLUT4 expres-
sion in adipocytes. These data suggest that in men fruc-
tose consumption likely contributes to increases of
hepatic insulin resistance both directly by providing sub-
strate for hepatic DNL leading to increased hepatic TG
accumulation and decreased hepatic insulin sensitivity
[7], and indirectly by increasing visceral adiposity [37],
while in women it is primarily a direct effect mediated
by increased hepatic DNL and lipid content.
Liver enzymes
There have been very few prospective investigations of
the effects of fructose consumption on the activity of the
liver enzymes GGT, AST and ALT in humans. However,
the results from one recent study suggest that short-
term fructose overfeeding does not alter AST or ALT ac-
tivities [38], and our results following 10 wks of fructose
consumption are in agreement with these findings.
Reports on the effects of fructose consumption on GGT
activity in humans are not available, and the results of
animal studies are not likely to be physiologically rele-
vant since these investigations have primarily been con-
ducted rats, which have been reported to have hepatic
and plasma GGT activities over 20-fold lower than
humans [39]. The results of the present study demon-
strate that prolonged fructose consumption leads to
marked increases of GGT activity in older, overweight/
obese adults (Table 2).
We also report that fructose-induced increases of
plasma GGT activity are positively associated with
increases of 24-h TG exposure, peak TG exposure and
the postprandial TG peak reported previously in these
same subjects [6] (Table 3, Figure 3). Martin et al. first
demonstrated that GGT activity is strongly associated
with postprandial plasma TG levels [40], which has since
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hypothesized that the upregulation of hepatic micro-
somal enzymes that results in increased TG synthesis
and DNL is accompanied by a concomitant increase in
GGT activity and speculated that this process could be
initiated by excessive carbohydrate intake [40]. The
increases of GGT activity in subjects consuming fructose
support the mechanism proposed by Martin et al. How-
ever, since GGT activity significantly decreased during
10 wks of glucose consumption, and these changes were
not related to measures of TG exposure, we suggest that,
under energy balanced conditions, it is not carbohydrate
in general (as speculated by Martin et al.) but rather in-
take of fructose specifically that mediates increases of
hepatic DNL, TG synthesis, and GGT activity.
GGT has been well established as a reliable marker of
increased hepatic lipid content and hepatic insulin resist-
ance [42]. In addition, elevations of plasma GGT activity
are positively associated with increases of visceral adi-
posity, and this relationship is independent of hepatic fat
content [43,44]. It has been suggested that fructose con-
sumption may contribute to increases of hepatic insulin
resistance both directly, by providing substrate for hep-
atic DNL leading to increased triglyceride accumulation
and novel PKC activation [6] and indirectly by increasing
visceral adiposity [37]. Based on the established associa-
tions between GGT activity, increased hepatic lipid con-
tent and visceral adiposity it is possible that either or
both of these mechanisms may contribute to increases
of GGT activity during fructose consumption. However,
the association of fructose-induced increases of GGT ac-
tivity with measures of TG exposure, but not with
increases of visceral adiposity, suggests that an increase
of intrahepatic lipid may be a primary mechanism. It
should also be noted that while increased GGT activity
is considered a sensitive marker of increased intrahepatic
lipid, it lacks the specificity of other liver enzymes such
as ALT. Elevations of GGT activity have also been shown
to be associated with increased oxidative stress, all-cause
mortality, and mortality from cancer and diabetes as
opposed to liver disease alone [45]. It is interesting but
not clear why the liver enzymes GGT, ALT and AST
decreased significantly from values measured during the
baseline complex carbohydrate diet in subjects consum-
ing glucose-sweetened beverages.
Elevations of plasma GGT activity are predictive of the
development of metabolic syndrome [14] and it has been
suggested that elevated GGT activity should be included
as an additional diagnostic risk factor for metabolic syn-
drome [46]. Our data suggest that under energy balanced
conditions, consumption of fructose at 25% of energy
requirements for 10 wks leads to greater increases of
plasma GGT activity in subjects with less than 3 MSRFs
compared to those with metabolic syndrome (≥3 MSRFs),despite comparable baseline values in both groups (see
Results). The reasons for this differential response are
unclear.Conclusions
We report new data demonstrating that consumption of
fructose at 25% of energy requirements for 10 wks, when
compared with isocaloric consumption of glucose, leads
to significant increases of fasting uric acid and 24-h uric
acid exposure, as well as circulating concentrations of
RBP-4 and GGT activity in overweight/obese adults. The
increases of GGT activity and RBP-4 levels in subjects
consuming fructose were associated with previously
reported increases of TG exposure [6], while increases of
fasting uric acid and 24-h uric acid exposure were not.
The effect of fructose to increase levels of RBP-4 is much
more robust in men than in women and this may be
related to the association of these changes with increases
of measures of TG exposure, which were also larger in
men [6]. Together, the results presented here indicate that
prolonged fructose consumption may contribute to the
development of the metabolic syndrome by increasing cir-
culating concentrations of uric acid, GGT activity (altered
hepatic function), and the production of RBP-4.
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